Gerard Evan is the Sir William Dunn Professor and Head of the Department of Biochemistry at the University of Cambridge, and Professor in the Departments of Pathology and Molecular and Cellular Pharmacology at the University of California, San Francisco.  He received his Ph.D. and completed his post-doctoral fellowship at Kings College and the University of California, respectively.  He is an editor of several journals, including among others Cancer Cell and Molecular Cancer Biology; and Founding Editor of Disease Models and Mechanisms.  Gerard has served on numerous important advisory boards in both the academic and private sector including the UK National Cancer Research Institute, the Advanced Cancer Therapies Thematic Center, at the Karolinska Institute, and Global Biotech Revolution Advisory Board.  His research and publications encompass a broad range of interest including identification of Myc-dependent apoptotic effectors, optimizing Myc inhibition as a therapeutic strategy in lung cancer and the role of p53 in tumor suppression and ageing.